Safety of off-label biologicals in systemic lupus erythematosus.

@article{Aringer2015SafetyOO,
  title={Safety of off-label biologicals in systemic lupus erythematosus.},
  author={Martin Aringer and Josef S Smolen},
  journal={Expert opinion on drug safety},
  year={2015},
  volume={14 2},
  pages={243-51}
}
INTRODUCTION The approval of belimumab and other advances in the field have narrowed the window for off-label use of biologicals in systemic lupus erythematosus (SLE). For consideration in severe and refractory disease, safety will play a major role. AREAS COVERED We reviewed the literature on safety aspects of off-label biological use in SLE. Significant… CONTINUE READING